Wednesday, 11 Dec 2019

You are here

Arhalofenate, URAT-1 Inhibitor, Being Developed for Gout

Good news for gout patients includes the recent approval of Zurampic (lesinurad), a URAT-1 inhibitor, and that effective urate-lowering therapy has significant long-term cardiovascular benefits. 

Fortunately, new drug development continues, including arhalofenate, a novel anti-inflammatory uricosuric. This agent's efficacy is based on being a URAT-1 inhibitor (blocks uric readsorbtion at the proximal tubule) and is also an anti-inflammatory drug.

A 12-week, randomized, controlled trial of 239 hyperuricemic gout patients (with recurrent flares) received daily arhalofenate 600 or 800 mg, allopurinol 300 mg, allopurinol 300 mg + 0.6 mg colchicine or placebo. The primary outcome was the flare incidence at 12 weeks.

The arhalofenate 800 mg had 46% fewer flares compared to allopurinol 300 mg (0.66 versus 1.24, p = 0.0056).  Arhalofenate 800 mg was also significantly better than placebo (p = 0.049), but did not achieve significance compared to allopurinol + colchicine (p = 0.091).

Serum urate significantly decreased -12.5% and -16.5% with arhalofenate 600 mg and 800 mg (p = 0.001 and p=0.0001) more than placebo. Adverse events were not different between groups. 

Arhalofenate appears to be an effective urate-lowering therapy and has shown to be more effective at decreasing gout flares compared to allopurinol.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Pegradicase+ImmTOR SEL-212 Shows Promising Results In Active Gout

Therapies targeting sUA accumulation or improving its excretion are widely used for treatment of symptoms and prevention of progression of gout for decades. Despite our best effort, there is still a significant amount of patients who remain symptomatic and/or experiences progressive joint damage and disability. Regardless of the cause, either its lack of compliance or poor tolerability, more effective treatments are needed.

PANLAR Ultrasound Study Group: Recommendations On Imaging Modalities In Gout

Gout is a systemic inflammatory disease with high potential for joint damage due to erosive changes and MSU deposits resulting in disability and chronic pain. Prompt diagnosis and effective treatment are key to better long term outcomes and decreased disability.

T2T Lowers Mortality in Gout

A Spanish prospective cohort of active, uncontrolled gout patients were followed and showed that failure to reach a target serum uric acid (sUA) level of 6 mg/dl (0.36 mmol/L) or less was associated with a 2-3 fold increase in mortality.

Novel Inhibition of MSU Crystal Inflammation

Researchers from Washington State University have shown that inhibition of tumor growth factor-β (TGF-β)-activated kinase 1 (TAK1) can effectively downregulate inflammatory mediators and suppress inflammation caused by gout.

Monosodium urate (MSU) crystals directly activate the inflammasome to produce a plethora of pro-inflammatory cytokines, including interleukin-1β (IL-1β). 

Patients Prefer Nurse Led Care for their Gout

Despite the well known, well publicized treat-to-target (T2T) goal of a serum uric acid (SUA) level < 6 mg/dl, this goal is seldom achieved (< 40%) in clinical practice and patient adherence has been unacceptably low. A recent study shows that nurse-led care led to better outcomes in gout including patient acceptability, long-term adherence, and less flares.